ES3060149T3 - Dosage forms for tyk2 inhibitors - Google Patents

Dosage forms for tyk2 inhibitors

Info

Publication number
ES3060149T3
ES3060149T3 ES20781719T ES20781719T ES3060149T3 ES 3060149 T3 ES3060149 T3 ES 3060149T3 ES 20781719 T ES20781719 T ES 20781719T ES 20781719 T ES20781719 T ES 20781719T ES 3060149 T3 ES3060149 T3 ES 3060149T3
Authority
ES
Spain
Prior art keywords
dosage forms
methyl
tyk2 inhibitors
dispersion
tyk2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20781719T
Other languages
English (en)
Inventor
Sherif Ibrahim Farag Badawy
Jonathan R Brown
Candice Y Choi
Christoph Gesenberg
Vivienne Gray
John Wynne Jones
Umesh Kestur
Balvinder S Vig
Xiaotian Yin
Christopher A Zordan
Corey Bloom
Ian Yates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES3060149T3 publication Critical patent/ES3060149T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan formulaciones y formas farmacéuticas estables y biodisponibles que comprenden una dispersión (por ejemplo, dispersión secada por pulverización) de 6-(ciclopropanoamido)-4-((2-metoxi-3-(1-metil-1H-1,2,4-triazol-3-il)fenil)amino)-N-(metil-d3)piridazina-3-carboxamida sólida amorfa (Fórmula (I); BMS-986165) en una matriz de polímero sólido para el tratamiento de enfermedades autoinmunes y autoinflamatorias como la enfermedad inflamatoria intestinal (EII) y la psoriasis. (Traducción automática con Google Translate, sin valor legal)
ES20781719T 2019-09-18 2020-09-18 Dosage forms for tyk2 inhibitors Active ES3060149T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962902218P 2019-09-18 2019-09-18
PCT/US2020/051342 WO2021055652A1 (en) 2019-09-18 2020-09-18 Dosage forms for tyk2 inhibitors

Publications (1)

Publication Number Publication Date
ES3060149T3 true ES3060149T3 (en) 2026-03-25

Family

ID=72670853

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20781719T Active ES3060149T3 (en) 2019-09-18 2020-09-18 Dosage forms for tyk2 inhibitors

Country Status (20)

Country Link
US (4) US20230255964A1 (es)
EP (3) EP4031109B1 (es)
JP (3) JP7719770B2 (es)
KR (2) KR20220066310A (es)
CN (8) CN114727948A (es)
AU (2) AU2020348783B2 (es)
BR (2) BR112022004216A2 (es)
CA (2) CA3151369A1 (es)
DK (1) DK4031110T3 (es)
ES (1) ES3060149T3 (es)
FI (1) FI4031110T3 (es)
HR (1) HRP20260058T1 (es)
IL (2) IL291452A (es)
LT (1) LT4031110T (es)
MX (4) MX2022003150A (es)
PL (1) PL4031110T3 (es)
PT (1) PT4031110T (es)
RS (1) RS67803B1 (es)
SI (1) SI4031110T1 (es)
WO (2) WO2021055652A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020348783B2 (en) * 2019-09-18 2026-04-16 Bristol-Myers Squibb Company Extended release dosage forms for Tyk2 inhibitors
EP4213813A1 (en) * 2020-09-18 2023-07-26 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors comprising swellable cores
IL305165A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
US12600721B2 (en) 2021-02-19 2026-04-14 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
CA3207819A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
IL311624A (en) 2021-09-23 2024-05-01 Bristol Myers Squibb Co Methods for treating hair loss disorders with TYK2 inhibitors
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用
KR20240090866A (ko) * 2021-10-28 2024-06-21 브리스톨-마이어스 스큅 컴퍼니 듀크라바시티닙의 국소 제제
WO2023181075A1 (en) * 2022-03-24 2023-09-28 Dr. Reddy's Laboratories Limited Amorphous solid dispersions of deucravacitinib and processes for the preparation thereof
AR128868A1 (es) * 2022-03-25 2024-06-19 Nimbus Lakshmi Inc Formulaciones de inhibidor de tyk2 y métodos para elaborarlas
WO2024176263A1 (en) * 2023-02-22 2024-08-29 Cipla Limited Deucravacitinib amorphous solid dispersions and polymorphs thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
ES2306646T3 (es) 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
ES2310164T3 (es) 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
US20020015731A1 (en) 1999-12-23 2002-02-07 Appel Leah E. Hydrogel-Driven Drug Dosage Form
WO2003000235A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
DE60322665D1 (de) 2002-02-01 2008-09-18 Pfizer Prod Inc Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
WO2008084698A1 (ja) 2006-12-28 2008-07-17 Astellas Pharma Inc. タクロリムス徐放性医薬組成物
CN101152158B (zh) 2007-08-21 2010-05-26 浙江大学 一种药物的双层芯渗透泵片的制备方法
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
WO2013013114A1 (en) 2011-07-21 2013-01-24 Bristol-Myers Squibb Company Bioavailable compositions of amorphous piperidinyl compounds
WO2014042945A1 (en) 2012-09-11 2014-03-20 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
WO2014043208A1 (en) * 2012-09-11 2014-03-20 Medivation Prostate Therapeutics, Inc. Formulations of enzalutamide
CN104968334B (zh) * 2012-09-28 2018-09-14 翁科埃斯克斯有限公司 包含噻吩并三唑并二氮杂卓化合物的药物制剂
MY194668A (en) 2012-11-08 2022-12-12 Bristol Myers Squibb Co Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses
CA2902424A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heterocyclic compounds and their uses
HRP20210764T1 (hr) 2017-03-30 2021-07-09 Bristol-Myers Squibb Company Postupak za pripremu 6-(ciklopropanamido)-4-((2-metoksi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazin-3-karboksamida
KR102848769B1 (ko) 2018-05-31 2025-08-20 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
AU2020348783B2 (en) * 2019-09-18 2026-04-16 Bristol-Myers Squibb Company Extended release dosage forms for Tyk2 inhibitors
EP4213813A1 (en) * 2020-09-18 2023-07-26 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors comprising swellable cores

Also Published As

Publication number Publication date
CN119745885A (zh) 2025-04-04
JP2025163082A (ja) 2025-10-28
CN114727949A (zh) 2022-07-08
CN119700773A (zh) 2025-03-28
SI4031110T1 (sl) 2026-03-31
CN119700772A (zh) 2025-03-28
CN119424433A (zh) 2025-02-14
MX2022003150A (es) 2022-04-06
JP2022548688A (ja) 2022-11-21
WO2021055652A1 (en) 2021-03-25
EP4031109C0 (en) 2026-02-18
US20220331315A1 (en) 2022-10-20
EP4031110B1 (en) 2025-12-24
BR112022004216A2 (pt) 2022-05-31
PL4031110T3 (pl) 2026-03-30
WO2021055651A1 (en) 2021-03-25
JP7812785B2 (ja) 2026-02-10
JP2022548687A (ja) 2022-11-21
PT4031110T (pt) 2026-02-03
HRP20260058T1 (hr) 2026-02-27
US20230255964A1 (en) 2023-08-17
IL291453A (en) 2022-05-01
AU2020349524A1 (en) 2022-03-31
LT4031110T (lt) 2026-02-25
BR112022004550A2 (pt) 2022-05-31
EP4031109B1 (en) 2026-02-18
DK4031110T3 (da) 2026-03-23
JP7719770B2 (ja) 2025-08-06
KR20220066310A (ko) 2022-05-24
CN119424434A (zh) 2025-02-14
EP4031109A1 (en) 2022-07-27
MX2025014308A (es) 2026-01-07
CN119424435A (zh) 2025-02-14
US12521390B2 (en) 2026-01-13
KR20220066105A (ko) 2022-05-23
CA3151137A1 (en) 2021-03-25
MX2025014307A (es) 2026-01-07
FI4031110T3 (fi) 2026-03-10
US20260083733A1 (en) 2026-03-26
AU2020348783B2 (en) 2026-04-16
EP4706778A2 (en) 2026-03-11
RS67803B1 (sr) 2026-03-31
EP4031110A1 (en) 2022-07-27
MX2022003146A (es) 2022-04-06
AU2020348783A1 (en) 2022-03-31
CN114727948A (zh) 2022-07-08
CA3151369A1 (en) 2021-03-25
US20260083734A1 (en) 2026-03-26
IL291452A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
ES3060149T3 (en) Dosage forms for tyk2 inhibitors
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
MX2017001671A (es) Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
ECSP18083443A (es) Formulaciones líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil) -pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
MX2017011270A (es) Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton.
CU23808B7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
CO7240408A2 (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
ES3057783T3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
CO2017005483A2 (es) Forma cristalina de sulfato de hidrógeno de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1- il)-pirazol[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
MX2017016217A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
CO2017011482A2 (es) Inhibidores de bromodominio
BR112023007912A2 (pt) Formas cristalinas de um composto inibidor de kras g12c
CL2024001231A1 (es) Formas cristalinas de derivados de quinazolina, preparación, composición y uso de estas
MX380301B (es) Prevención o tratamiento de enfermedades urinarias o gotosas.
CO2021014253A2 (es) Formulación de tableta vaginal
MX2022008285A (es) Tratamiento de la nefropatia membranosa, enfermedad relacionada con igg4 y sindrome antifosfolipido utilizando el inhibidor de la btk 2-[(3r)-3-[4-amino-3-(2- fluoro-4-fenoxi-fenil)pirazolo[3,4-d] pirimidin-1-il]piperidin-1-carbonil]-4-metil-4-[4- (oxetan-3-il)piperazin-1-il]pent-2-enonitrilo.
AR109859A1 (es) Inhibidor de bromodominio
MX2021004553A (es) Composiciones farmaceuticas y metodos para fabricar formulaciones de dosificacion solidas bajo demanda.
GT200600242A (es) Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil)ftalazin-1-ilo] no micronizado, y sus sales
AR126542A1 (es) Formas sólidas y formulaciones de un inhibidor de quinasas tam y c-met
AR126784A1 (es) Formas sólidas de 7-[[(1s)-1-[4-[(1s)-2-ciclopropil-1-(4-prop-2-enoilpiperazin-1-il)etil]fenil]etil]amino]-1-etil-4h-pirimido[4,5-d][1,3]oxazin-2-ona
AR067861A1 (es) Composicion farmaceutica que comprende la combinacion de un agente anticonvulsivamente y un agente benzodiazepinico, indicada para el control y tratamiento de trastornos convulsivos y sindromes epilepticos